牛牛AI助理已提取核心訊息
Avenue Therapeutics, a pharmaceutical company, has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review its Registration Statement on Form S-3, which was filed on January 24, 2024. The SEC's communication, dated January 29, 2024, was addressed to Alix MacLean, CEO of Avenue Therapeutics, and highlighted that the responsibility for the accuracy and adequacy of disclosures lies with the company and its management. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Avenue Therapeutics has been directed to contact Tamika Sheppard at the SEC with any further questions.
Avenue Therapeutics, a pharmaceutical company, has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review its Registration Statement on Form S-3, which was filed on January 24, 2024. The SEC's communication, dated January 29, 2024, was addressed to Alix MacLean, CEO of Avenue Therapeutics, and highlighted that the responsibility for the accuracy and adequacy of disclosures lies with the company and its management. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Avenue Therapeutics has been directed to contact Tamika Sheppard at the SEC with any further questions.
生命科學公司財務部已告知製藥公司Avenue Therapeutics，美國證券交易委員會（SEC）不會審查其於2024年1月24日提交的S-3表格註冊聲明。美國證券交易委員會於2024年1月29日致函Avenue Therapeutics首席執行官阿利克斯·麥克萊恩，並強調披露準確性和充分性的責任在於公司及其管理層。美國證券交易委員會還引用了第460和461條，這兩條規則與加快註冊程序的請求有關。如有任何其他問題，Avenue Therapeutics已被指示聯繫美國證券交易委員會的塔米卡·謝潑德。
生命科學公司財務部已告知製藥公司Avenue Therapeutics，美國證券交易委員會（SEC）不會審查其於2024年1月24日提交的S-3表格註冊聲明。美國證券交易委員會於2024年1月29日致函Avenue Therapeutics首席執行官阿利克斯·麥克萊恩，並強調披露準確性和充分性的責任在於公司及其管理層。美國證券交易委員會還引用了第460和461條，這兩條規則與加快註冊程序的請求有關。如有任何其他問題，Avenue Therapeutics已被指示聯繫美國證券交易委員會的塔米卡·謝潑德。
有用
沒用